Poly Medicure Ltd
Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices.[1]
- Market Cap ₹ 26,250 Cr.
- Current Price ₹ 2,586
- High / Low ₹ 3,358 / 1,361
- Stock P/E 89.0
- Book Value ₹ 256
- Dividend Yield 0.12 %
- ROCE 23.6 %
- ROE 19.1 %
- Face Value ₹ 5.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 31.9% CAGR over last 5 years
Cons
- Stock is trading at 10.1 times its book value
- Promoter holding has decreased over last quarter: -3.47%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Part of Nifty Smallcap 250 BSE Allcap Nifty 500 BSE SmallCap Nifty 500 Multicap 50:25:25
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
259 | 322 | 390 | 411 | 454 | 519 | 610 | 687 | 785 | 922 | 1,115 | 1,375 | 1,522 | |
206 | 246 | 304 | 323 | 361 | 397 | 479 | 520 | 569 | 707 | 847 | 1,013 | 1,116 | |
Operating Profit | 53 | 76 | 86 | 88 | 93 | 122 | 131 | 166 | 216 | 215 | 267 | 362 | 406 |
OPM % | 20% | 24% | 22% | 21% | 21% | 23% | 22% | 24% | 28% | 23% | 24% | 26% | 27% |
0 | 11 | 28 | 8 | 14 | 16 | 20 | 21 | 22 | 40 | 38 | 60 | 77 | |
Interest | 7 | 9 | 10 | 10 | 8 | 12 | 14 | 20 | 11 | 6 | 11 | 14 | 13 |
Depreciation | 13 | 14 | 19 | 21 | 24 | 29 | 37 | 41 | 48 | 54 | 57 | 64 | 73 |
Profit before tax | 33 | 63 | 85 | 65 | 75 | 97 | 100 | 126 | 180 | 195 | 237 | 344 | 397 |
Tax % | 30% | 30% | 27% | 27% | 27% | 27% | 35% | 24% | 25% | 25% | 25% | 25% | |
24 | 45 | 62 | 48 | 55 | 71 | 65 | 96 | 136 | 147 | 179 | 258 | 295 | |
EPS in Rs | 2.75 | 5.11 | 7.07 | 5.47 | 6.25 | 8.00 | 7.41 | 10.86 | 14.17 | 15.28 | 18.69 | 26.91 | 30.24 |
Dividend Payout % | 9% | 20% | 18% | 27% | 40% | 25% | 27% | 18% | 18% | 16% | 16% | 11% |
Compounded Sales Growth | |
---|---|
10 Years: | 16% |
5 Years: | 18% |
3 Years: | 21% |
TTM: | 22% |
Compounded Profit Growth | |
---|---|
10 Years: | 21% |
5 Years: | 32% |
3 Years: | 24% |
TTM: | 26% |
Stock Price CAGR | |
---|---|
10 Years: | 27% |
5 Years: | 65% |
3 Years: | 41% |
1 Year: | 71% |
Return on Equity | |
---|---|
10 Years: | 18% |
5 Years: | 17% |
3 Years: | 16% |
Last Year: | 19% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 11 | 22 | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 | 51 |
Reserves | 101 | 124 | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 | 2,541 |
49 | 67 | 79 | 82 | 101 | 133 | 161 | 207 | 137 | 127 | 149 | 174 | 161 | |
53 | 73 | 89 | 76 | 85 | 94 | 112 | 126 | 121 | 163 | 187 | 214 | 300 | |
Total Liabilities | 214 | 286 | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,052 |
92 | 123 | 165 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 | 972 | |
CWIP | 8 | 20 | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 | 62 |
Investments | 4 | 3 | 4 | 4 | 3 | 17 | 8 | 25 | 354 | 346 | 132 | 167 | 1,090 |
110 | 140 | 185 | 187 | 227 | 264 | 321 | 354 | 422 | 499 | 732 | 748 | 928 | |
Total Assets | 214 | 286 | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,052 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
39 | 66 | 63 | 63 | 56 | 75 | 106 | 128 | 119 | 123 | 191 | 266 | |
-31 | -58 | -59 | -31 | -56 | -88 | -101 | -107 | -436 | -85 | -179 | -241 | |
-8 | 5 | -6 | -31 | -0 | 16 | -5 | -21 | 317 | -35 | -13 | -20 | |
Net Cash Flow | 0 | 13 | -2 | 1 | 0 | 3 | 1 | 1 | 0 | 3 | -1 | 5 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 61 | 52 | 59 | 74 | 77 | 79 | 77 | 68 | 72 | 82 | 77 | 72 |
Inventory Days | 149 | 142 | 148 | 114 | 194 | 161 | 186 | 241 | 217 | 218 | 237 | 205 |
Days Payable | 99 | 101 | 101 | 76 | 131 | 96 | 123 | 142 | 111 | 115 | 105 | 89 |
Cash Conversion Cycle | 111 | 94 | 106 | 111 | 140 | 144 | 139 | 166 | 179 | 185 | 209 | 188 |
Working Capital Days | 56 | 31 | 45 | 65 | 81 | 94 | 83 | 73 | 107 | 116 | 112 | 100 |
ROCE % | 27% | 33% | 30% | 26% | 24% | 26% | 22% | 25% | 22% | 17% | 18% | 24% |
Documents
Announcements
-
Statement Of Deviation(S) Or Variation(S) If Any Of Utilization Of Proceeds Received From Qualified Institutions Placement (QIP) Under Regulation 32 Of SEBI(LODR) Regulations 2015.
13 Nov - Statement of fund utilization from QIP proceeds.
-
Monitoring Agency Report For The Quarter Ended 30Th September, 2024 - QIP Under Regulation 32 Of SEBI (LODR) Regulation, 2015
13 Nov - Monitoring Agency Report for QIP for Q3 2024.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
6 Nov - Submission of Q2 FY24 earnings conference call transcript.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
29 Oct - Audio recording of earnings conference call available.
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
28 Oct - Allotment of Equity Shares under ESOP, Scheme 2020.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024TranscriptPPTREC
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptPPT
-
Nov 2023TranscriptPPT
-
Aug 2023TranscriptPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Jul 2021TranscriptPPT
-
May 2021Transcript PPT
-
Feb 2021TranscriptNotesPPT
Product Portfolio
It is a medical devices company with product portfolio comprises of more than 130 SKUs of medical devices in the product verticals of infusion therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others. [1]